Skip to content
The Policy VaultThe Policy Vault

Carafate — Blue Cross Blue Shield of Alabama

Short-term (up to 8 weeks) treatment of active duodenal ulcer

Initial criteria

  • The prescriber has provided information that the use of the tablet formulation is not clinically appropriate for the patient
  • AND the patient does NOT have any FDA labeled contraindications to the requested agent

Approval duration

12 months